Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
antibiotic-Huashan Hospital refers to a specific post-operative medication regimen used in a clinical trial (NCT03141580) conducted by Huashan Hospital to evaluate the efficacy of LED photobiomodulation therapy following mandibular third molar extraction. Although labeled as 'Antibiotic' in the trial's intervention list, the regimen is a multi-drug combination consisting of **cefaclor** (a second-generation cephalosporin antibiotic), **metronidazole** (a nitroimidazole antimicrobial), and **ibuprofen** (a nonsteroidal anti-inflammatory drug). Cefaclor provides coverage against aerobic bacteria by inhibiting cell wall synthesis, metronidazole targets anaerobic pathogens by disrupting DNA, and ibuprofen is utilized to manage post-surgical pain and inflammation by inhibiting cyclooxygenase enzymes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cefaclor + metronidazole + ibuprofen.